Dechavanne Célia auteur aut IRD Dechavanne S. auteur aut IRD Bosch J. auteur aut IRD Metral S. auteur aut IRD Redinger K. R. auteur aut IRD Watson Q. D. auteur aut IRD Ratsimbasoa A. C. auteur aut IRD Roeper B. auteur aut IRD Krishnan S. auteur aut IRD Fong R. auteur aut IRD Bennett S. auteur aut IRD Carias L. auteur aut IRD Chen E. D. auteur aut IRD Salinas N. D. auteur aut IRD Ghosh A. auteur aut IRD Tolia N. H. auteur aut IRD Woost P. G. auteur aut IRD Jacobberger J. W. auteur aut IRD Colin Y. auteur aut IRD Gamain B. auteur aut IRD King C. L. auteur aut IRD Zimmerman P. A. auteur aut IRD text journalArticle eng text/pdf born digital access The erythrocyte silent Duffy blood group phenotype in Africans is thought to confer resistance to Plasmodium vivax blood-stage infection. However, recent studies report P. vivax infections across Africa in Fy-negative individuals. This suggests that the globin transcription factor 1 (GATA-1) SNP underlying Fy negativity does not entirely abolish Fy expression or that P. vivax has developed a Fy-independent red blood cell (RBC) invasion pathway. We show that RBCs and erythroid progenitors from in vitro differentiated CD34 cells and from bone marrow aspirates from Fy-negative samples express a functional Fy on their surface. This suggests that the GATA-1 SNP does not entirely abolish Fy expression. Given these results, we developed an in vitro culture system for P. vivax and show P. vivax can invade erythrocytes from Duffy-negative individuals. This study provides evidence that Fy is expressed in Fy-negative individuals and explains their susceptibility to P. vivax with major implications and challenges for P. vivax malaria eradication. specialized AFRIQUE 050 052 020 31 12 [22 p.] 2023 1931-3128 https://www.documentation.ird.fr/hor/fdi:010088919 10.1016/j.chom.2023.10.019 1931-3128 [F B010088919] https://www.documentation.ird.fr/hor/fdi:010088919 https://www.documentation.ird.fr/intranet/publi/2024-02/010088919.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2024-02-07 2025-02-24 fdi:010088919 fre